ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1274

New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody

Sho Sasaki1, Akira Ishii 2, Mai Sugiyama 2, Yuto Izumi 2, Yoko Nakagome 2, Kazuki Hirano 3, Takayoshi Kurabayashi 1, Shinichi Nogi 4, Noriko Sasaki 2, Chiho Yamada 2 and Shinji Sato 5, 1Tokai Universitiy School of Medicine, Isehara, Japan, 2Tokai University School of Medicine, Isehara, Japan, 3Tokai University School of Medicine, Isehara, 4National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, 5Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Antibodies, dermatomyositis, interstitial lung disease, polymyositis and Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS antibody has a stronger association with ILD compared with PM/DM, the clinical characteristics of anti-KS antibody have not been examined in detail. The aim of this study was to clarify the clinical and immunological features of patients with anti-KS antibody.

Methods: PM/DM or ILD patients who visited Tokai University Hospital between 2010 and 2018 were screened. Autoantibodies were identified by immunoprecipitation assays and all clinical and immunological data were collected retrospectively. ILD was diagnosed based on the findings of computed tomography. The clinical and immunological features of anti-KS positive patients were assessed. Comparisons between anti-KS positive patients and other anti-ARS positive patients were examined. Statistical analyses were performed using the Fisher’s exact test.

Results: Fifteen anti-KS positive patients were identified. Ten were female and 5 were male, with an average age of 62.5 years (range, 40-80 years). Final diagnoses were 6 patients with ILD alone, 4 with clinically amyopathic DM (CADM) and ILD, 3 with Sjögren’s Syndrome (SjS) and ILD, one each with rheumatoid arthritis (RA) and ILD, or CADM/SjS overlap and ILD. Although various diagnoses were determined for these patients, all patients had ILD with chronic onset and a chronic clinical course. Five patients (33%) presented with dyspnea as an initial symptom. On high-resolution computed tomography analysis, 10 (67%) of 15 patients revealed radiographic features of non-specific interstitial pneumonia (NSIP) and 4 (27%) had a usual interstitial pneumonia (UIP) pattern and one (7%) had an organizing pneumonia (OP) pattern. As for skin manifestations, 9 (60%) had mechanic’s hands, 4 (27%) had Gottron’s sign and one (7%) each had the heliotrope rash or palmar papules. Interestingly, all anti-KS positive showed no clinical muscle weakness or serum creatine kinase elevation. Moreover, seven of 15 patients (47%) had sicca syndrome and were positive for anti-SSA and/or anti-SSB antibodies. There was a significantly high frequency of sicca syndrome in anti-KS positive patients compared with anti-Jo-1 positive patients (47% vs. 12%, P=0.02).

 

Conclusion: These results suggest that anti-KS antibody positive patients might form a distinguishable subset that is closely associated with sicca syndrome and CADM as well as chronic type ILD.


Disclosure: S. Sasaki, None; A. Ishii, None; M. Sugiyama, None; Y. Izumi, None; Y. Nakagome, None; K. Hirano, None; T. Kurabayashi, None; S. Nogi, None; N. Sasaki, None; C. Yamada, None; S. Sato, MBL, 7, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD, 7.

To cite this abstract in AMA style:

Sasaki S, Ishii A, Sugiyama M, Izumi Y, Nakagome Y, Hirano K, Kurabayashi T, Nogi S, Sasaki N, Yamada C, Sato S. New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/new-aspects-of-clinical-and-immunological-characteristics-in-patients-with-anti-ks-antibody/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-aspects-of-clinical-and-immunological-characteristics-in-patients-with-anti-ks-antibody/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology